Menu
Search
|

Menu

Close
X

Juniper Pharmaceuticals Inc JNP.OQ (NASDAQ Stock Exchange Global Select Market)

8.60 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 8.60
Open --
Volume --
3m Avg Volume 9,031
Today’s High --
Today’s Low --
52 Week High 8.90
52 Week Low 3.65
Shares Outstanding (mil) 10.84
Market Capitalization (mil) 50.97
Forward P/E 6.24
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
25
FY16
55
FY15
38
EPS (USD)
FY17
-0.127
FY16
0.516
FY15
-0.142
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
6.24
32.90
Price to Sales (TTM)
vs sector
0.88
5.77
Price to Book (MRQ)
vs sector
1.26
5.41
Price to Cash Flow (TTM)
vs sector
5.04
23.42
Total Debt to Equity (MRQ)
vs sector
9.71
16.52
LT Debt to Equity (MRQ)
vs sector
8.43
12.22
Return on Investment (TTM)
vs sector
20.65
14.43
Return on Equity (TTM)
vs sector
23.82
16.13

EXECUTIVE LEADERSHIP

James Geraghty
Independence Chairman of the Board, Since 2015
Salary: --
Bonus: --
Alicia Secor
Chief Executive Officer, Director, Since 2016
Salary: $170,883.00
Bonus: $56,391.00
Jeffrey Young
Senior Vice President, Finance, Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer), Since 2017
Salary: --
Bonus: --
Nikin Patel
Chief Operating Officer, Director, Since 2013
Salary: $253,157.00
Bonus: $89,785.00
Jennifer Good
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

33 Arch St Ste 3110
BOSTON   MA   02110-1424

Phone: +1617.6391500

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

SPONSORED STORIES